EyePoint Pharmaceuticals (EYPT) Competitors

EyePoint Pharmaceuticals logo
$6.50 +0.19 (+3.01%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$6.62 +0.13 (+1.92%)
As of 02/14/2025 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EYPT vs. TXG, TRNS, CTKB, SENS, LAB, ALNT, AEHR, QTRX, QSI, and NAUT

Should you be buying EyePoint Pharmaceuticals stock or one of its competitors? The main competitors of EyePoint Pharmaceuticals include 10x Genomics (TXG), Transcat (TRNS), Cytek Biosciences (CTKB), Senseonics (SENS), Standard BioTools (LAB), Allient (ALNT), Aehr Test Systems (AEHR), Quanterix (QTRX), Quantum-Si (QSI), and Nautilus Biotechnology (NAUT). These companies are all part of the "measuring and control equipment" industry.

EyePoint Pharmaceuticals vs.

EyePoint Pharmaceuticals (NASDAQ:EYPT) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.

EyePoint Pharmaceuticals received 406 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 70.29% of users gave EyePoint Pharmaceuticals an outperform vote while only 52.17% of users gave 10x Genomics an outperform vote.

CompanyUnderperformOutperform
EyePoint PharmaceuticalsOutperform Votes
466
70.29%
Underperform Votes
197
29.71%
10x GenomicsOutperform Votes
60
52.17%
Underperform Votes
55
47.83%

In the previous week, 10x Genomics had 59 more articles in the media than EyePoint Pharmaceuticals. MarketBeat recorded 60 mentions for 10x Genomics and 1 mentions for EyePoint Pharmaceuticals. EyePoint Pharmaceuticals' average media sentiment score of 1.84 beat 10x Genomics' score of -0.22 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
EyePoint Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
10x Genomics
4 Very Positive mention(s)
2 Positive mention(s)
14 Neutral mention(s)
25 Negative mention(s)
1 Very Negative mention(s)
Neutral

EyePoint Pharmaceuticals has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.

99.4% of EyePoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 4.7% of EyePoint Pharmaceuticals shares are owned by company insiders. Comparatively, 10.0% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

EyePoint Pharmaceuticals has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than EyePoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EyePoint Pharmaceuticals$46.02M9.64-$70.79M-$2.00-3.25
10x Genomics$618.73M2.41-$255.10M-$1.53-8.05

EyePoint Pharmaceuticals presently has a consensus price target of $26.63, indicating a potential upside of 309.62%. 10x Genomics has a consensus price target of $20.57, indicating a potential upside of 67.11%. Given EyePoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe EyePoint Pharmaceuticals is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EyePoint Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00
10x Genomics
1 Sell rating(s)
9 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.35

10x Genomics has a net margin of -28.93% compared to EyePoint Pharmaceuticals' net margin of -226.57%. 10x Genomics' return on equity of -25.07% beat EyePoint Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
EyePoint Pharmaceuticals-226.57% -43.01% -31.63%
10x Genomics -28.93%-25.07%-19.41%

Summary

EyePoint Pharmaceuticals beats 10x Genomics on 9 of the 17 factors compared between the two stocks.

Get EyePoint Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EYPT vs. The Competition

MetricEyePoint PharmaceuticalsAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$451.82M$5.58B$5.86B$9.14B
Dividend YieldN/A0.44%5.27%3.99%
P/E Ratio-3.258.1117.7915.56
Price / Sales9.643.96466.0675.86
Price / CashN/A40.4546.1438.90
Price / Book1.152.167.285.05
Net Income-$70.79M-$10.70M$3.19B$222.81M
7 Day Performance0.15%-1.26%2.82%2.10%
1 Month Performance-10.59%-2.12%4.49%2.15%
1 Year Performance-77.04%-22.87%22.00%16.56%

EyePoint Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EYPT
EyePoint Pharmaceuticals
1.6918 of 5 stars
$6.50
+3.0%
$26.63
+309.6%
-77.0%$451.82M$46.02M0.00120
TXG
10x Genomics
4.4312 of 5 stars
$12.06
-15.4%
$23.79
+97.2%
-74.6%$1.46B$618.73M-7.881,240Earnings Report
Analyst Forecast
Analyst Revision
High Trading Volume
TRNS
Transcat
3.5377 of 5 stars
$77.82
+1.3%
$111.50
+43.3%
-22.1%$724.39M$272.20M42.061,104Positive News
CTKB
Cytek Biosciences
1.5136 of 5 stars
$5.15
-3.7%
$6.50
+26.3%
-38.5%$662.73M$193.01M-64.30500Short Interest ↓
SENS
Senseonics
2.7048 of 5 stars
$1.02
-2.4%
$2.00
+97.0%
+71.3%$604.26M$22.39M-7.8190Gap Up
LAB
Standard BioTools
3.0646 of 5 stars
$1.32
-4.7%
$2.88
+118.6%
-45.1%$489.52M$106.34M-1.85620
ALNT
Allient
4.2631 of 5 stars
$24.57
+1.5%
$29.33
+19.4%
-6.4%$413.73M$578.63M27.922,287
AEHR
Aehr Test Systems
3.8025 of 5 stars
$10.71
-0.7%
$25.00
+133.5%
-39.4%$318.08M$66.22M14.2790Short Interest ↓
QTRX
Quanterix
2.4162 of 5 stars
$7.84
-3.4%
$23.25
+196.4%
-69.3%$302.14M$132.53M-7.40460Gap Down
QSI
Quantum-Si
2.3684 of 5 stars
$2.00
-2.2%
$3.42
+71.3%
+14.7%$284.71M$1.08M-3.12150Positive News
NAUT
Nautilus Biotechnology
3.3798 of 5 stars
$1.70
+4.9%
$3.58
+110.8%
-39.6%$213.45MN/A-3.04130

Related Companies and Tools


This page (NASDAQ:EYPT) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners